Today is national #RareDiseaseDay! Did you know approximately 1 in 10 people in the US suffer from a rare disease? Join us in recognizing all those impacted by #raredisease on this important day. #AbeonaSupports #AbeonaTherapeutics

This morning Abeona announced that target enrollment has been achieved in our pivotal Phase 3 VIITAL™ Study of EB-101 in RDEB. Read our press release: bit.ly/3Jc2hmc

Abeona CEO Vish Seshadri, Ph.D., will participate in a panel discussion on cell therapies and rare diseases at the Cantor Fitzgerald Virtual Rare Orphan Disease Summit. Read our press release: bit.ly/3DqBT64

Abeona’s CTO and Head of Research, Brian Kevany Ph.D., will share new NHP data on a novel AIM™ AAV capsid showing superior macular transduction at ARVO this week. Read our press release: bit.ly/3KyfCV

Today, Abeona announced new preclinical data on AAV204, a novel AAV capsid. Read our press release: bit.ly/3MRt20w

This morning we announced positive topline data from our pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).

We are honored to support EB Research Partnership and work alongside the entire EB community on our journey towards treatments and ultimately a cure.

Abeona Therapeutics is looking forward to celebrating Dr. Anna Bruckner. We are a proud sponsor of #debraBenefit2024. See you in California!

#NEWS: We’re proud to announce the #FDAApproval of the first and only autologous cell sheet-based gene therapy for the treatment of wounds in people with recessive dystrophic epidermolysis bullosa (#RDEB). Learn more: bit.ly/ZEVASKYN_FDAAp… For full PI: bit.ly/ZEVASKYN_USPI

Today, The Lancet published the results from our study evaluating the efficacy and safety of the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with #RDEB. Read the article: bit.ly/3ZJUeau #MedX

‼️Announcement: A new Qualified Treatment Center in the San Francisco Bay area is now accepting patients with recessive dystrophic epidermolysis bullosa (RDEB) for treatment with our FDA-approved cell-based gene therapy. Learn more: bit.ly/ZEVASKYNNewQTC… #MedEd #raredisease

Abeona Therapeutics reported our second quarter 2025 financial results and corporate updates. Listen to the highlights and recent developments: bit.ly/AbeonaFinancial #Investors #Earnings $ABEO

This September, Abeona Therapeutics will be attending two key #investor conferences. 🗓 Cantor Global Healthcare Conference 2025 🗓 H.C. Wainwright & Co. 27th Annual Global Investment Conference Access the webcasts: bit.ly/AbeonaEvents $ABEO #Investing

We have announced the activation of our newest Qualified Treatment Center for patients living with recessive dystrophic epidermolysis bullosa (#RDEB) for treatment with our FDA-approved cell-based gene therapy. Read more: bit.ly/ChildrensHospi… #MedEd #RareDisease

We are proud to share that one of our gene therapy candidates has been selected for the U.S. FDA Rare Disease Endpoint Advancement (RDEA) Pilot Program. Discover what this means for Abeona: bit.ly/AbeonaFDARDEAS… #meded

We’re excited to announce the appointment of James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs at Abeona Therapeutics. Read more 👉 bit.ly/AbeonaJamesGow… #Biotech #Innovation #Leadership

We stand with the epidermolysis bullosa (EB) community in recognizing and raising awareness for #EBAwarenessWeek. Join us in supporting the cause and help us bring visibility to this rare and painful genetic disorder. #EBWeek #WeFightEB